Utilizing network pharmacology to explore potential mechanisms of YiSui NongJian formula in treating myelodysplastic syndrome

References

• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Longo DL. Myelodysplastic syndromes. N Engl J Med. 2020;383(14):1358–1374.
   PubMed Web of Science ®Google Scholar
• Hidalgo-Lopez JE, Kanagal-Shamanna R, Quesada AE, et al. Progress in Myelodysplastic Syndromes: clinicopathologic correlations and immune checkpoints. Clin Lymphoma Myeloma Leuk. 2017;17:S16–S25.
   Web of Science ®Google Scholar
• Makishima H. Founder and subclonal mutations in myelodysplastic syndromes and related myeloid neoplasms. Best Pract Res Clin Haematol. 2020;33(3):101189.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Chien KS, Montalban-Bravo G. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. Am J Hematol. 2020;95(11):1399–1420.
   PubMed Web of Science ®Google Scholar
• Hou HY, Zhou YM. Treatment of 30 cases of myelodysplastic syndrome with self-formulated prescription of filling marrow and detoxification. Global Traditional Chinese Medicine. 2019;12:884–887.
   Google Scholar
• Guo M, Lang HX, Liao Q, et al. Observation on the curative effect of YiSui Ointment Formula combined with EPO in the treatment of myelodysplastic syndrome. Journal of Sichuan Traditional Chinese Medicine. 2016;34:83–85.
   Google Scholar
• XQ D, Guo M, HY C, et al. Clinical observation on the treatment of myelodysplastic syndrome-refractory anemia by traditional Chinese medicine of toniying qi and nourishing blood and promoting blood circulation. Guangxi Medical Journal. 2018;40:2604–2607.
   Google Scholar
• Hu KW, Sun YL, Le ZS, et al. Clinical study of tonifying qi, nourishing Yin and promoting blood circulation in the treatment of myelodysplastic syndrome. Journal of Beijing University of Traditional Chinese Medicine. 72-3. 1994: 39–44.
   Google Scholar
• Li S, Zhang B. Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin J Nat Med. 2013;11(2):110–120.
   PubMed Web of Science ®Google Scholar
• Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682–690.
   PubMed Web of Science ®Google Scholar
• Zhang R, Zhu X, Bai H, et al. Network Pharmacology Databases for Traditional Chinese Medicine: review and Assessment. Front Pharmacol. 2019;10:123.
   PubMed Web of Science ®Google Scholar
• Ru J, Li P, Wang J, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform. 2014;6(1):13.
   PubMed Web of Science ®Google Scholar
• Liu Z, Guo F, Wang Y, et al. BATMAN-TCM: a bioinformatics analysis tool for molecular mechANism of Traditional Chinese Medicine. Sci Rep. 2016;6(1):21146.
   PubMedGoogle Scholar
• Wang Y, Zhang S, Li F, et al. Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics. Nucleic Acids Res. 2020;48(D1):D1031–D41.
   PubMed Web of Science ®Google Scholar
• Xue CC, Zhang AL, Greenwood KM, et al. Traditional chinese medicine: an update on clinical evidence. J Altern Complement Med. 2010;16(3):301–312.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Li Y, Zhou L, et al. Prevention and treatment of COVID-19 using Traditional Chinese Medicine: a review. Phytomedicine. 2020;153308.
   PubMed Web of Science ®Google Scholar
• How CW, Ong YS, Low SS, et al. How far have we explored fungi to fight cancer? Semin Cancer Biol. 2021. DOI:10.1016/j.semcancer.2021.03.009
   PubMed Web of Science ®Google Scholar
• Shen X, Si Y, Wang Z, et al. Quercetin inhibits the growth of human gastric cancer stem cells by inducing mitochondrial-dependent apoptosis through the inhibition of PI3K/Akt signaling. Int J Mol Med. 2016;38(2):619–626.
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhang X, Xu M, et al. Quercetin attenuates collagen-induced arthritis by restoration of Th17/Treg balance and activation of Heme Oxygenase 1-mediated anti-inflammatory effect. Int Immunopharmacol. 2018;54:153–162.
   PubMed Web of Science ®Google Scholar
• Lee WJ, Wu LF, Chen WK, et al. Inhibitory effect of luteolin on hepatocyte growth factor/scatter factor-induced HepG2 cell invasion involving both MAPK/ERKs and PI3K-Akt pathways. Chem Biol Interact. 2006;160(2):123–133.
   PubMed Web of Science ®Google Scholar
• Hong Z, Cao X, Li N, et al. Luteolin is effective in the non-small cell lung cancer model with L858R/T790M EGF receptor mutation and erlotinib resistance. Br J Pharmacol. 2014;171(11):2842–2853.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Luo T, Li S, et al. Effects of crocetin on proliferation, apoptosis and migration of human MG63 myeloma cells. Anatomy Research. 2015;37:54–58.
   Google Scholar
• Zhou Z, Liu SP, Liang Q LZ, et al. Baicalein enhances AS2O3 induced pro-apoptotic effects in primary liver cancer via PI3K/AKT pathway. Journal of Modern Oncology. 2019;27:1661–1668.
   Google Scholar
• Tan JJ, Fan Z, Wang DD, et al. Effect of baicalein on mitochondrial apoptosis pathway in human epidermal squamous cell carcinoma A431 cells. Guangxi Medical Journal. 2017;39:1895–1899.
   Google Scholar
• Yan MY, Chien SY, Kuo SJ, et al. Tanshinone IIA inhibits BT-20 human breast cancer cell proliferation through increasing caspase 12, GADD153 and phospho-p38 protein expression. Int J Mol Med. 2012;29(5):855–863.
   PubMed Web of Science ®Google Scholar
• Wang H, Su X, Fang J, et al. Tanshinone IIA Attenuates Insulin Like Growth Factor 1 -Induced Cell Proliferation in PC12 Cells through the PI3K/Akt and MEK/ERK Pathways. Int J Mol Sci. 2018;19(9):2719.
   Google Scholar
• Cheng HL, Hsieh MJ, Yang JS, et al. Nobiletin inhibits human osteosarcoma cells metastasis by blocking ERK and JNK-mediated MMPs expression. Oncotarget. 2016;7(23):35208–35223.
   PubMedGoogle Scholar
• Shi MD, Liao YC, Shih YW, et al. Nobiletin attenuates metastasis via both ERK and PI3K/Akt pathways in HGF-treated liver cancer HepG2 cells. Phytomedicine. 2013;20(8–9):743–752.
   PubMed Web of Science ®Google Scholar
• Bachegowda L, Gligich O, Mantzaris I, et al. Signal transduction inhibitors in treatment of myelodysplastic syndromes. J Hematol Oncol. 2013;6(1):50.
   PubMedGoogle Scholar
• Ishibashi M, Tamura H, Ogata K. Disease progression mechanism in myelodysplastic syndromes: insight into the role of the microenvironment. Leuk Res. 2011;35(11):1449–1452.
   PubMed Web of Science ®Google Scholar
• Zhang XF, Zhao L, Xu P. Effect of Compound Shenlu Granule on Apoptosis of CD34 + Cells in Lower-risk MDS Bone Marrow Based on p38MAPK Pathway. Chinese Journal of Experimental Traditional Medical Formulae. 2017;23:152–157.
   Google Scholar
• Liu GY, Sabatini DM. mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol. 2020;21:183–203.
   PubMed Web of Science ®Google Scholar
• You L, Jin S, Zhu L, et al. Autophagy, autophagy-associated adaptive immune responses and its role in hematologic malignancies. Oncotarget. 2017;8(7):12374–12388.
   PubMedGoogle Scholar
• Su N, Qu Y, Li Y. [Autophagy and hematologic malignancies]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014;22(4):1129–1132.
   PubMedGoogle Scholar
• Puissant A, Robert G, Auberger P. Targeting autophagy to fight hematopoietic malignancies. Cell Cycle. 2010;9(17):3470–3478.
   PubMed Web of Science ®Google Scholar
• Nencioni A, Cea M, Montecucco F, et al. Autophagy in blood cancers: biological role and therapeutic implications. Haematologica. 2013;98(9):1335–1343.
   PubMed Web of Science ®Google Scholar
• Dong Z, Liang S, Hu J, et al. Autophagy as a target for hematological malignancy therapy. Blood Rev. 2016;30(5):369–380.
   PubMed Web of Science ®Google Scholar
• Houwerzijl EJ, Pol HW, Blom NR, et al. Erythroid precursors from patients with low-risk myelodysplasia demonstrate ultrastructural features of enhanced autophagy of mitochondria. Leukemia. 2009;23(5):886–891.
   PubMed Web of Science ®Google Scholar
• Houwerzijl EJ, Blom NR, Van Der Want JJ, et al. Megakaryocytic dysfunction in myelodysplastic syndromes and idiopathic thrombocytopenic purpura is in part due to different forms of cell death. Leukemia. 2006;20(11):1937–1942.
   PubMed Web of Science ®Google Scholar
• Bouchliou I, Miltiades P, Nakou E, et al. Th17 and Foxp3(+) T regulatory cell dynamics and distribution in myelodysplastic syndromes. Clin Immunol. 2011;139:350–359.
   PubMed Web of Science ®Google Scholar
• SY K, Ingram W, Hayden J, et al. CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood. 2007;110(3):847–850.
   PubMed Web of Science ®Google Scholar
• Kordasti SY, Afzali B, Lim Z, et al. IL-17-producing CD4+T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol. 2009;145(1):64–72.
   PubMed Web of Science ®Google Scholar
• Ma Q, Ma L, Xue HB. Advances on the relationship between PI3K/AKT/mTOR signaling pathway and Th17 cells. Journal of Binzhou Medical University. 2020;43:225–228.
   Google Scholar
• Low SS, Pan YX, Ji DZ, et al. Smartphone-based portable electrochemical biosensing system for detection of circulating microRNA-21 in saliva as a proof-of-concept. Sensor Actuat B-Chem. 2020;308.
   PubMed Web of Science ®Google Scholar